Citigroup
NTLA icon

Citigroup’s Intellia Therapeutics NTLA Stock Holding History

Citigroup’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100
Closed -$3.16K – 5809
2023
Q3 		$3.16K Buy
+100
New +$3.88K ﹤0.01% 4843
2022
Q4 		– Sell
-25,000
Closed -$1.4M – 5898
2022
Q3 		$1.4M Buy
+25,000
New +$1.55M ﹤0.01% 2450
2020
Q2 		– Sell
-2,800
Closed -$34K – 7630
2020
Q1 		$34K Sell
2,800
-1,200
-30% -$16.2K ﹤0.01% 6321
2019
Q4 		$59K Sell
4,000
-2,200
-35% -$30.6K ﹤0.01% 6182
2019
Q3 		$83K Sell
6,200
-1,500
-19% -$23.9K ﹤0.01% 5798
2019
Q2 		$126K Buy
7,700
+5,400
+235% +$84.9K ﹤0.01% 5655
2019
Q1 		$39K Sell
2,300
-7,500
-77% -$112K ﹤0.01% 6540
2018
Q4 		$134K Sell
9,800
-500
-5% -$9.29K ﹤0.01% 5407
2018
Q3 		$295K Buy
10,300
+2,200
+27% +$64K ﹤0.01% 4857
2018
Q2 		$222K Buy
8,100
+400
+5% +$9.69K ﹤0.01% 4956
2018
Q1 		$162K Buy
+7,700
New +$189K ﹤0.01% 5174

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup's NTLA Position: Q1 2026 in Review

Citigroup reduced its Intellia Therapeutics (NTLA) stake by 84% in Q1 2026, selling an estimated $2.48M and leaving 36,757 shares worth $471K. The position accounts for ﹤0.01% of the portfolio, ranked #3587.

Citigroup first reported a position in NTLA in Q2 2016 and has held it in 39 quarters since. The position peaked at $24.6M in Q1 2022. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Citigroup held 36,757 shares of Intellia Therapeutics worth $471K as of Q1 2026.
  • Citigroup sold 194,399 Intellia Therapeutics shares in Q1 2026, an estimated $2.48M.
  • Intellia Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3587 holding.
  • Citigroup first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 39 quarters since.
  • Citigroup's Intellia Therapeutics position peaked at $24.6M in Q1 2022.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.